Celldex Q4 2023 net loss $43.3M; cash $423.6M; Phase 3 CSU study planned for summer 2024

Celldex Therapeutics, Inc.

2023-FY EPS reported -$2.92 revenue$6,883,000

Q4 2023 net loss $43.3M ($0.83/share) vs $26.5M ($0.56) in Q4 2022; FY net loss $141.4M ($2.92/share).
Revenue $4.1M in Q4 2023 vs $1.6M in Q4 2022, primarily from Rockefeller University manufacturing agreements.
Cash, cash equivalents and marketable securities $423.6M at Dec 31, 2023 vs $235.3M at Sep 30, 2023; $216.2M raised in Nov 2023 offering.
Barzolvolimab: Positive Phase 2 CSU 12-week data; Phase 3 CSU studies expected to start summer 2024; 52-week data in 2H 2024.
Phase 2 CIndU enrollment nearing completion (data 2H 2024); Phase 2 PN study to start early 2024; cash runway into 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Celldex Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.

Period: the fourth quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 26, 2024, Celldex Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and year ended 2023.

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

Celldex Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-000966

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.